A cost-effectiveness model for analyzing two varicella vaccination strategies.

Am J Health Syst Pharm

Department of Pharmaceutical Services, Palmetto Richland Memorial Hospital, Columbia, SC 29203, USA.

Published: December 1998

A model for estimating the cost-effectiveness of a program for vaccinating employees at a health care institution against varicella zoster virus (VZV) was studied. Three outcomes of varicella vaccination--cost-effectiveness, reduction in employee infections, and reduction in patient exposures--were stratified to estimate the incremental costs of vaccinating three employee groups. The groups consisted of all employees (vaccinate-all group), employees providing direct patient care (direct care group), and employees working in high-risk patient care areas (high-risk group). Two strategies for employee vaccination were used: screen (by antibody titer testing) and then vaccinate, and vaccination alone. A model was used to estimate the various outcomes of the vaccination program. The model supported the screen, then vaccinate strategy of vaccinating employees, at a cost savings of about $50 per employee. Vaccination of all employees prevented 35 employee infections and 674 patient exposures for every 10,000 potentially susceptible employees. The cost of preventing one employee infection was about $15,000, and the cost of preventing one patient exposure was about $775. An employee vaccination program is a good investment in preventing patient exposures to VZV and may be cost-effective compared with only screening employees.

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajhp/55.suppl_4.S4DOI Listing

Publication Analysis

Top Keywords

employee vaccination
12
employees
8
vaccinating employees
8
employee infections
8
group employees
8
patient care
8
vaccination program
8
employees cost
8
patient exposures
8
cost preventing
8

Similar Publications

Background: HER2-targeted therapies have revolutionized the treatment of HER2-positive breast cancer patients, leading to significant improvements in tumor response rates and survival. However, resistance and incomplete response remain considerable challenges. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a novel therapeutic strategy for the management of dyslipidemia by enhancing the clearance of low-density lipoprotein cholesterol receptors, however recent evidence also shows links between PCSK9 and cancer cells.

View Article and Find Full Text PDF

NTHi killing activity is reduced in COPD patients and is associated with a differential microbiome.

Respir Res

January 2025

Microbial Antibodies and Technologies, Research and Early Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.

Chronic obstructive pulmonary disease (COPD) is a chronic lung disease characterized by airway obstruction and inflammation. Non-typeable Haemophilus influenzae (NTHi) lung infections are common in COPD, promoting frequent exacerbations and accelerated lung function decline. The relationship with immune responses and NTHi are poorly understood.

View Article and Find Full Text PDF

Background: SIREN is a healthcare worker cohort study aiming to determine COVID-19 incidence, duration of immunity and vaccine effectiveness across 135 NHS organisations in four UK nations. Conducting an intensive prospective cohort study during a pandemic was challenging. We designed an evolving retention programme, informed by emerging evidence on best practice.

View Article and Find Full Text PDF

The rapid development and worldwide distribution of COVID-19 vaccines is a remarkable achievement of biomedical research and logistical implementation. However, these developments are associated with the risk of a surge of substandard and falsified (SF) vaccines, as illustrated by the 184 incidents with SF and diverted COVID-19 vaccines which have been reported during the pandemic in 48 countries, with a paucity of methods for their detection in supply chains. In this context, matrix-assisted laser desorption ionisation-time of flight (MALDI-ToF) mass spectrometry (MS) is globally available for fast and accurate analysis of bacteria in patient samples, offering a potentially accessible solution to identify SF vaccines.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!